Sclerostin monoclonal antibody in the treatment of osteoporosis

Wang Zi-wei; Tian Jing

doi:10.3969/j.issn.2095-4344.2013.33.019

Abstract： BACKGROUND:Sclerostin can negatively regulate the bone metabolism, and the sclerostin monoclonal antibody can antagonize the negative regulation effect, inhibit bone resorption and promote bone formation. OBJECTIVE:To explore the mechanism and application progress of sclerostin monoclonal antibody in the treatment of osteoporosis. METHODS:An online search of PubMed database, CNKI database, VIP database and Wanfang database between May 2005 and May 2013 was performed by the first author to search the related articles with the key words of“osteoporosis, antibody, sclerostin, Wnt, SOST”in both English and Chinese. Articles related to sclerostin monoclonal antibody were included. For the articles in the same field, those published earlier or in the authorized journals were preferred. RESULTS AND CONCLUSION:A total of 170 articles were obtained after initial search, and final y 54 articles related to sclerostin monoclonal antibody were included for review according to the inclusion criteria. The sclerostin can block Wnt pathway through combining with low-density lipoprotein receptor-related protein 5/6, thus inhibiting the differentiation and mineralization of osteoblasts. By specifical y binding to sclerostin, the sclerosin monoclonal antibody can indirectly promote bone formation and restrain bone absorption which has great significance in the treatment of osteoporosis. Meanwhile, compared with the other treatment method, the specific targeting of sclerostin and the binding specificity of sclerostin monoclonal antibody provide application advantages for the treatment of osteoporosis.